Evidence Hub

Coccidioidomycosis: an emerging disease in Taiwan

Li YC, Lin MW, Wu UI, Lu CW, Chen PH, Tsai TM, Kuo SW, Hsieh MS et al.

Journal of the Formosan Medical Association = Taiwan yi zhi, 2026

Abstract

Coccidioidomycosis is an endemic fungal disease occurring almost exclusively on the American continent. Until 2021, only sporadic imported cases were observed in Taiwan. However, a dramatic surge in the number of cases over the past 3 years has been observed. Hence, we conducted a retrospective case series study between January 1, 2000, and May 31, 2025, at the National Taiwan University Hospital. Thirteen patients were included in the study. Most were workers or businessmen related to the Taiwan semiconductor factory expansion in Arizona, United States of America since 2020. All patients were surgically diagnosed in the chronic or latent phase using video-assisted thoracic surgery. Given the recent dramatic surge in imported cases of coccidioidomycosis, probably linked to the rapid expansion of Taiwan's semiconductor industry in the United States, we addressed the importance of obtaining travel and occupational histories and an urgent need of rapid diagnostic testing for coccidioidomycosis among healthcare providers in Taiwan.

How strong is the evidence?

Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free